The European Commission Has Approved BeiGene's Tevimbra (Tislelizumab) In Combination With Chemotherapy For The First-line Treatment Of Esophageal Squamous Cell Carcinoma And Gastric Or Gastroesophageal Junction Adenocarcinoma
The European Commission Has Approved BeiGene's Tevimbra (Tislelizumab) In Combination With Chemotherapy For The First-line Treatment Of Esophageal Squamous Cell Carcinoma And Gastric Or Gastroesophageal Junction Adenocarcinoma
歐洲委員會已批准百濟神州的Tevimbra（替雷利單抗）與化療聯合用於食管鱗狀細胞癌及胃或胃食管交界腺癌的一線治療。
The European Commission Has Approved BeiGene's Tevimbra (Tislelizumab) In Combination With Chemotherapy For The First-line Treatment Of Esophageal Squamous Cell Carcinoma And Gastric Or Gastroesophageal Junction Adenocarcinoma
歐洲委員會已批准百濟神州的Tevimbra（替雷利單抗）與化療聯合用於食管鱗狀細胞癌及胃或胃食管交界腺癌的一線治療。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間